PT2813491T - Derivado de cicloalcano - Google Patents

Derivado de cicloalcano

Info

Publication number
PT2813491T
PT2813491T PT137463733T PT13746373T PT2813491T PT 2813491 T PT2813491 T PT 2813491T PT 137463733 T PT137463733 T PT 137463733T PT 13746373 T PT13746373 T PT 13746373T PT 2813491 T PT2813491 T PT 2813491T
Authority
PT
Portugal
Prior art keywords
cycloalkane derivative
cycloalkane
derivative
Prior art date
Application number
PT137463733T
Other languages
English (en)
Portuguese (pt)
Inventor
Shinozuka Tsuyoshi
Kobayashi Hiroyuki
Suzuki Sayaka
Tanaka Kyosuke
Kimoto Hiroko
Domon Yuki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PT2813491T publication Critical patent/PT2813491T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT137463733T 2012-02-09 2013-02-08 Derivado de cicloalcano PT2813491T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012259122 2012-11-27

Publications (1)

Publication Number Publication Date
PT2813491T true PT2813491T (pt) 2017-02-10

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137463733T PT2813491T (pt) 2012-02-09 2013-02-08 Derivado de cicloalcano

Country Status (30)

Country Link
US (3) US8889741B2 (OSRAM)
EP (2) EP3144300B1 (OSRAM)
JP (2) JP5997710B2 (OSRAM)
KR (1) KR20140127238A (OSRAM)
CN (1) CN104185629B (OSRAM)
AU (1) AU2013218592B2 (OSRAM)
BR (1) BR112014019478A2 (OSRAM)
CA (1) CA2864222C (OSRAM)
CO (1) CO7151511A2 (OSRAM)
CY (1) CY1118572T1 (OSRAM)
DK (1) DK2813491T3 (OSRAM)
ES (2) ES2659434T3 (OSRAM)
HR (1) HRP20161713T1 (OSRAM)
HU (2) HUE037048T2 (OSRAM)
IL (1) IL234014A (OSRAM)
IN (1) IN2014MN01577A (OSRAM)
LT (1) LT2813491T (OSRAM)
MX (1) MX349354B (OSRAM)
NZ (1) NZ628096A (OSRAM)
PH (2) PH12014501804A1 (OSRAM)
PL (1) PL2813491T3 (OSRAM)
PT (1) PT2813491T (OSRAM)
RS (1) RS55671B1 (OSRAM)
RU (1) RU2635354C2 (OSRAM)
SG (1) SG11201404707VA (OSRAM)
SI (1) SI2813491T1 (OSRAM)
SM (2) SMT201700053T1 (OSRAM)
TW (1) TWI612042B (OSRAM)
WO (1) WO2013118854A1 (OSRAM)
ZA (1) ZA201405801B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
BR112014010271A2 (pt) * 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
TW201400446A (zh) 2012-05-22 2014-01-01 Genentech Inc N-取代之苯甲醯胺及其使用方法
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
CA2905613C (en) * 2013-03-14 2017-11-28 Daiichi Sankyo Company, Limited Drug for respiratory diseases
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック, インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
KR20180067561A (ko) 2015-09-28 2018-06-20 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
US10316026B2 (en) 2015-11-06 2019-06-11 Daiichi Sankyo Company, Limited Method for removing dimethoxybenzyl group
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
ES3022639T3 (en) * 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
CR20190236A (es) * 2016-10-17 2019-09-09 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10836758B2 (en) * 2016-10-27 2020-11-17 Bristol-Myers Squibb Company Acyl sulfonamide NaV1.7 inhibitors
JP7022751B2 (ja) * 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CA3076202A1 (en) 2017-09-20 2019-03-28 Abm Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019165290A1 (en) * 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
BR112021000209A2 (pt) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos
EP3844158A1 (en) 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CN113164461A (zh) * 2018-12-26 2021-07-23 拉夸里亚创药株式会社 作为Nav1.7及Nav1.8阻断剂的杂环衍生物
US20240241265A1 (en) * 2023-01-18 2024-07-18 Qualcomm Incorporated Virtual positioning signal measurements

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
RU2007146769A (ru) * 2005-05-16 2009-06-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные и их применение в качестве модуляторов ионых каналов
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
EA020460B1 (ru) * 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
WO2012004714A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
EP2590972B1 (en) * 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
EP2590951B1 (en) * 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
BR112014010271A2 (pt) * 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Also Published As

Publication number Publication date
EP2813491B1 (en) 2016-11-02
LT2813491T (lt) 2017-02-10
CN104185629A (zh) 2014-12-03
MX2014009637A (es) 2015-06-23
SMT201700053T1 (it) 2017-03-08
TW201339152A (zh) 2013-10-01
WO2013118854A1 (ja) 2013-08-15
US20140045862A1 (en) 2014-02-13
HUE037048T2 (hu) 2018-08-28
PH12014501804B1 (en) 2014-11-17
EP2813491A4 (en) 2015-08-12
ZA201405801B (en) 2015-12-23
ES2659434T3 (es) 2018-03-15
RU2014136463A (ru) 2016-03-27
JPWO2013118854A1 (ja) 2015-05-11
NZ628096A (en) 2016-06-24
DK2813491T3 (en) 2017-02-13
RS55671B1 (sr) 2017-06-30
US8889741B2 (en) 2014-11-18
SI2813491T1 (sl) 2017-02-28
JP2017008093A (ja) 2017-01-12
PL2813491T3 (pl) 2017-08-31
PH12015502675A1 (en) 2017-04-24
JP6154052B2 (ja) 2017-06-28
ES2613078T3 (es) 2017-05-22
KR20140127238A (ko) 2014-11-03
JP5997710B2 (ja) 2016-09-28
IL234014A0 (en) 2014-09-30
SMT201700053B (it) 2017-03-08
IL234014A (en) 2017-09-28
TWI612042B (zh) 2018-01-21
MX349354B (es) 2017-07-24
IN2014MN01577A (OSRAM) 2015-05-08
EP3144300B1 (en) 2017-12-20
AU2013218592A1 (en) 2014-09-18
US20150018551A1 (en) 2015-01-15
CY1118572T1 (el) 2017-07-12
CA2864222A1 (en) 2013-08-15
AU2013218592B2 (en) 2016-12-22
HK1203503A1 (en) 2015-10-30
CO7151511A2 (es) 2014-12-29
CN104185629B (zh) 2017-10-13
SG11201404707VA (en) 2014-10-30
US9493448B2 (en) 2016-11-15
EP3144300A1 (en) 2017-03-22
HUE031450T2 (en) 2017-07-28
BR112014019478A2 (pt) 2019-05-28
US9845313B2 (en) 2017-12-19
CA2864222C (en) 2016-10-25
HRP20161713T1 (hr) 2017-02-10
US20170001984A1 (en) 2017-01-05
PH12014501804A1 (en) 2014-11-17
RU2635354C2 (ru) 2017-11-13
EP2813491A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
ZA201405801B (en) Cycloalkane derivative
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
DK3327112T3 (en) Agse-deficient stamme
DK2830816T3 (en) Hidtil ukendt coatingkoncept
IL238221A0 (en) self-injector
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
GB201220843D0 (en) Compound
SG11201406871UA (en) Benzamide derivative
IL236295A (en) The history of indanesulfamide
EP2874517A4 (en) SEAT LIFTING ARRANGEMENT
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
EP2905847A4 (en) TOGETHER
EP2920142A4 (en) MÉTHANOFULLERRÈNES
ZA201405108B (en) Substituted phenylazole derivative
PL2873660T3 (pl) Pochodna indolokarboksyamidu
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201216448D0 (en) Compound
GB201211594D0 (en) Language
GB201219170D0 (en) Pull
GB201220595D0 (en) Keysafe application
GB201222353D0 (en) Auto-injector
GB201213503D0 (en) Auto-injector
GB201213502D0 (en) Auto-injector
GB201213500D0 (en) Auto-injector